一种特殊亚型：揭示 KRAS 野生型胰腺癌的潜在干预和巨大价值。
A special subtype: Revealing the potential intervention and great value of KRAS wildtype pancreatic cancer.
机构信息
Department of Pancreatic Surgery, Zhongshan Hospital, Fudan University, Shanghai, China; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China.
Department of Pancreatic Surgery, Zhongshan Hospital, Fudan University, Shanghai, China; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China.
出版信息
Biochim Biophys Acta Rev Cancer. 2022 Jul;1877(4):188751. doi: 10.1016/j.bbcan.2022.188751. Epub 2022 Jun 19.
Pancreatic ductal adenocarcinoma (PDAC) is the predominant form of pancreatic cancer and has devastating consequences on affected families and society. Its dismal prognosis is attributed to poor specificity of symptoms during early stages. It is widely believed that PDAC patients with the wildtype (WT) KRAS gene benefit more from currently available treatments than those with KRAS mutations. The oncogenic genetic changes alternations generally found in KRAS wildtype PDAC are related to either the KRAS pathway or microsatellite instability/mismatch repair deficiency (MSI/dMMR), which enable the application of tailored treatments based on each patient's genetic characteristics. This review focuses on targeted therapies against alternative tumour mechanisms in KRAS WT PDAC.
胰腺导管腺癌（PDAC）是胰腺癌的主要形式，给患者家庭和社会带来了毁灭性的后果。其预后不良的原因在于早期症状缺乏特异性。人们普遍认为，KRAS 基因野生型（WT）的 PDAC 患者比 KRAS 基因突变型患者从现有治疗中获益更多。在 KRAS 野生型 PDAC 中通常发现的致癌基因突变改变与 KRAS 通路或微卫星不稳定/错配修复缺陷（MSI/dMMR）有关，这使得可以根据每个患者的遗传特征应用针对性的治疗方法。本综述重点介绍了针对 KRAS WT PDAC 中替代肿瘤机制的靶向治疗方法。
Zotero 插件